Cargando…

Fludarabine in the treatment of chronic lymphocytic leukemia: a review

Fludarabine (FAMP) is the most effective and most extensively studied purine analog in indolent B-cell malignancies. Its use is indicated for first-and second-line treatment of B-cell chronic lymphocytic leukemia (B-CLL). FAMP as a single agent has produced superior response rates and progression-fr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ricci, Francesca, Tedeschi, Alessandra, Morra, Enrica, Montillo, Marco
Formato:	Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2009
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2697528/ https://www.ncbi.nlm.nih.gov/pubmed/19436622

Ejemplares similares

Alemtuzumab in the treatment of fludarabine refractory B-cell chronic lymphocytic leukemia (CLL)
por: Montillo, Marco, et al.
Publicado: (2008)

The spectrum of use of rituximab in chronic lymphocytic leukemia
por: Tedeschi, Alessandra, et al.
Publicado: (2010)

Therapy-Related Myeloid Neoplasms in Chronic Lymphocytic Leukemia and Waldenstrom’s Macroglobulinemia
por: Ricci, Francesca, et al.
Publicado: (2011)

Development of fludarabine formulations in the treatment of chronic lymphocytic leukemia
por: Janssens, Ann, et al.
Publicado: (2009)

Clinical utility and patient considerations in the use of ofatumumab in chronic lymphocytic leukemia
por: Frustaci, Anna Maria, et al.
Publicado: (2015)

Fludarabine Treatment of Patient with Chronic Lymphocytic Leukemia Induces a Digital Ischemia
por: Soyaltin, Utku Erdem, et al.
Publicado: (2016)

MicroRNAs involvement in fludarabine refractory chronic lymphocytic leukemia
por: Ferracin, Manuela, et al.
Publicado: (2010)

T-cell large granular lymphocytic leukemia: treatment experience with fludarabine
por: Costa, Renata Oliveira, et al.
Publicado: (2012)

Cost-effectiveness of adding rituximab to fludarabine and cyclophosphamide for treatment of chronic lymphocytic leukemia in Ukraine
por: Mandrik, Olena, et al.
Publicado: (2015)

Fludarabine-resistance associates with ceramide metabolism and leukemia stem cell development in chronic lymphocytic leukemia
por: Huang, Chunfa, et al.
Publicado: (2018)

Matrix Metalloproteinase-9 Is Involved in Chronic Lymphocytic Leukemia Cell Response to Fludarabine and Arsenic Trioxide
por: Amigo-Jiménez, Irene, et al.
Publicado: (2014)

Progressive multifocal leukoencephalopathy developing in a fludarabine naïve patient with chronic lymphocytic leukemia
por: Ooi, Melissa G, et al.
Publicado: (2009)

Determination of genes and microRNAs involved in the resistance to fludarabine in vivo in chronic lymphocytic leukemia
por: Moussay, Etienne, et al.
Publicado: (2010)

A phase II Japanese trial of fludarabine, cyclophosphamide and rituximab for previously untreated chronic lymphocytic leukemia
por: Izutsu, Koji, et al.
Publicado: (2020)

Fludarabine-Cyclophosphamide-Rituximab Treatment in Chronic Lymphocytic Leukemia, Focusing on Long Term Cytopenias Before and After the Era of Targeted Therapies
por: Szász, Róbert, et al.
Publicado: (2021)

Outpatient-Based Therapy of Oral Fludarabine and Subcutaneous Alemtuzumab for Asian Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia
por: Hwang, William Y. K., et al.
Publicado: (2009)

Gene expression of INPP5F as an independent prognostic marker in fludarabine-based therapy of chronic lymphocytic leukemia
por: Palermo, G, et al.
Publicado: (2015)

A Case of Hemophagocytic Lymphohistiocytosis in a Patient with Chronic Lymphocytic Leukemia after Treatment with Fludarabine, Cyclophosphamide, and Rituximab Chemotherapy, with Autopsy Findings
por: Tiong, Ing S., et al.
Publicado: (2012)

Management of adverse events associated with idelalisib treatment in chronic lymphocytic leukemia and follicular lymphoma: A multidisciplinary position paper
por: Cuneo, Antonio, et al.
Publicado: (2018)

Synergistic Activity of Deguelin and Fludarabine in Cells from Chronic Lymphocytic Leukemia Patients and in the New Zealand Black Murine Model
por: Rebolleda, Nerea, et al.
Publicado: (2016)

DNA polymerase ν gene expression influences fludarabine resistance in chronic lymphocytic leukemia independently of p53 status
por: Grgurevic, Srdana, et al.
Publicado: (2018)

Fludarabine modulates composition and function of the T cell pool in patients with chronic lymphocytic leukaemia
por: Gassner, Franz Josef, et al.
Publicado: (2010)

High rate of minimal residual disease responses in young and fit patients with IGHV mutated chronic lymphocytic leukemia treated with front-line fludarabine, cyclophosphamide, and intensified dose of ofatumumab (FCO2)
por: Mauro, Francesca R., et al.
Publicado: (2020)

Magnetic resonance imaging may simulate progressive multifocal leucoencephalopathy in a patient with chronic lymphocytic leukemia after fludarabine therapy
por: Kalita, J., et al.
Publicado: (2008)

Long-term survival in a patient with progressive multifocal leukoencephalopathy after therapy with rituximab, fludarabine and cyclophosphamide for chronic lymphocytic leukemia
por: Garrote, Heidys, et al.
Publicado: (2015)

Obinutuzumab plus fludarabine and cyclophosphamide in previously untreated, fit patients with chronic lymphocytic leukemia: a subgroup analysis of the GREEN study
por: Bosch, Francesc, et al.
Publicado: (2019)

Analysis of Data on Fludarabine, Cyclophosphamide, and Rituximab Chemoimmunotherapy for Chronic Lymphocytic Leukemia Shows High Patient Heterogeneity and the Need for More Consideration of Individualized Treatment
por: Xu, Xiaoli, et al.
Publicado: (2022)

Fludarabine-induced bradycardia in a patient with refractory leukemia
por: Chung-Lo, Woei, et al.
Publicado: (2010)

EZN-2208 treatment suppresses chronic lymphocytic leukaemia by interfering with environmental protection and increases response to fludarabine
por: Valsecchi, Roberta, et al.
Publicado: (2020)

Chemo-immunotherapy for Older Patients with Chronic Lymphocytic Leukemia – Time to Retire?
por: Scarfò, Lydia, et al.
Publicado: (2019)

Chronic Lymphocytic Leukemia
por: Vaisitti, Tiziana, et al.
Publicado: (2020)

HS1, a Lyn Kinase Substrate, Is Abnormally Expressed in B-Chronic Lymphocytic Leukemia and Correlates with Response to Fludarabine-Based Regimen
por: Frezzato, Federica, et al.
Publicado: (2012)

Ibrutinib plus fludarabine, cyclophosphamide and rituximab (iFCR) as initial treatment in chronic lymphocytic leukemia/ small lymphocytic leukemia with or without TP53 aberrations: a prospective real-world study in Chinese cohort
por: Miao, Yi, et al.
Publicado: (2023)

Virus reactivations and serology patterns following first-line therapy with alemtuzumab or fludarabine-based combination therapy in patients with chronic lymphocytic leukemia
por: Karlsson, C, et al.
Publicado: (2011)

Assessment of microRNA expression in leukemic cells as predictors of sensitivity to purine nucleoside analogs, fludarabine and cladribine, in chronic lymphocytic leukemia patients
por: Szymczyk, Agnieszka, et al.
Publicado: (2019)

Thiotepa-busulfan-fludarabine compared to busulfan-fludarabine for sibling and unrelated donor transplant in acute myeloid leukemia in first remission
por: Saraceni, Francesco, et al.
Publicado: (2017)

Telomerase Contributes to Fludarabine Resistance in Primary Human Leukemic Lymphocytes
por: Shawi, May, et al.
Publicado: (2013)

Hepatitis B Reactivation in a HBsAg-Negative, HBcAb-Positive Patient Receiving Fludarabine for the Treatment of Chronic Lymphocytic Leukaemia
por: Toscanini, Federica, et al.
Publicado: (2011)

The rate of in vitro fludarabine-induced peripheral blood and bone marrow cell apoptosis may predict the chemotherapy outcome in patients with chronic lymphocytic leukemia
por: Podhorecka, Monika, et al.
Publicado: (2015)

Targeted Treatment of Chronic Lymphocytic Leukemia: Clinical Utility of Acalabrutinib
por: Vitale, Candida, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_k7lk8rskp0ermnu05n0tercq79